PATIENT-CENTRIC IN ALL WE DO
Underlying the company’s mission is its enduring commitment to putting the needs of patients first. It’s why Biohaven operates with intention in following science without limitations and acts with urgency in advancing life-changing new medicines – mindful that patients are waiting and days matter.
CHALLENGING THE STATUS QUO
To execute its mission, Biohaven is advancing a differentiated late-stage drug development portfolio, while investing in a robust and integrated drug discovery engine that supports its dedication to novel scientific and clinical research.
FOLLOWING SCIENCE ON BEHALF OF PATIENTS
Biohaven is dedicated to following science, continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital.
Katy M.
Katy M.Principal Scientist,
In Vivo Science
FOLLOWING SCIENCE ON BEHALF OF PATIENTS
Biohaven is dedicated to following science, continuously striving to evolve our approach to drug discovery and development to help people live healthier lives. To enhance our ability to deliver enduring value, we have combined internal research and development with intellectual property licensed from companies and institutions including Pfizer, Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC, and Massachusetts General Hospital.
Katy M.
Senior Research Scientist
PROVEN DRUG DEVELOPMENT CAPABILITIES
Biohaven is developing drug candidates based on our proprietary platforms, all of which are modular in design to enable rapid generation of novel therapies for the treatment of diseases with high unmet medical needs.
Our ability to optimize success across our numerous drug development programs is driven by our proven expertise in clinic execution, where we have demonstrated the ability to operate with unmatched speed and efficiency.
We are advancing an extensive portfolio of late- and early-stage programs across multiple therapeutic indications in neuroscience, immunology and oncology.
DEMONSTRATING THE POWER OF DIGITAL TRANSFORMATION
As a modern pharmaceutical company, Biohaven also has established an agile operating model with a culture of innovation that extends across the R&D lifecycle to all aspects of business. We pride ourselves on being a tech-savvy company and a leader in the use of digital tools and technologies to increase engagement and enhance the success of our novel treatments.
REALIZING OUR MISSION
We believe our future is bright. We intend to realize our mission by delivering a paradigm shift by creating opportunities for breakthrough science with our early-stage R&D engine, executing diligently on our commercial launches, harnessing our digital technology leadership, and building our global partnerships.
We’re just getting started.